Comparative Pharmacology
Head-to-head clinical analysis: RAYALDEE versus VECTICAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAYALDEE versus VECTICAL.
RAYALDEE vs VECTICAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rayaldee (calcifediol) is a vitamin D3 analog that is converted to the active hormone calcitriol by 1-alpha-hydroxylase in the kidney. It acts as a vitamin D receptor agonist, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and suppressing parathyroid hormone (PTH) secretion. In CKD patients, it lowers elevated PTH levels.
VECTICAL (calcitriol) is a vitamin D analog that binds to vitamin D receptors (VDRs) in target tissues, increasing intestinal calcium absorption, renal calcium reabsorption, and enhancing osteoclast activity to mobilize calcium from bone, thereby raising serum calcium levels.
30 mcg orally once daily at bedtime.
1-2 mcg orally twice daily, increased every 2-4 weeks based on serum calcium and PTH levels. Maximum dose: 4 mcg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 14-19 hours, reflecting the extended-release formulation designed for once-daily dosing.
Mean terminal elimination half-life is approximately 3.7 hours (range 2.5–5.5 hours) in healthy adults. Clinically, steady-state is achieved within 2–3 days.
Primarily fecal via biliary excretion (70-80%); renal excretion accounts for <10% of total clearance.
Primarily hepatobiliary (74%) and fecal (14%), with renal excretion accounting for <1% of the administered dose as unchanged drug. Enterohepatic recirculation occurs.
Category C
Category C
Vitamin D Analog
Vitamin D Analog